hit counter

Multiple System Atrophy nOH: 41.7% Diagnosed, 40.0% Suspicious

MHD featured image for multiple system atrophy nOH burden and blood pressure screening.

A 259-person multiple system atrophy survey found diagnosed neurogenic orthostatic hypotension in 41.7% of respondents, while another 40.0% had upright symptoms suspicious for nOH without a diagnosis and 21.2% reported never having upright blood pressure measured.1 The operational problem is simple: in MSA, low blood pressure on standing can be disabling, missed, and still undertreated …

Read more

Ubiquinol for Multiple System Atrophy: First Positive Repurposing Trial

Photoreal illustration of misfolded alpha-synuclein in glial cells with drug molecule motifs, representing repurposed-drug therapeutics in MSA.

Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …

Read more